<DOC>
	<DOCNO>NCT00134901</DOCNO>
	<brief_summary>Cocaine one widely abused drug United States . Memantine type drug call NMDA receptor antagonist . It work decrease normal excitement brain . NMDA receptor antagonist show reduce cocaine-induced dopamine release animal model , well lessen condition cocaine cue . The purpose study determine effectiveness memantine prevent relapse cocaine use cocaine dependent individual . In addition , study determine whether memantine produce good result placebo decrease cocaine craving , psychological symptom , functional impairment , discontinuation treatment cocaine dependent individual .</brief_summary>
	<brief_title>Effectiveness Memantine Treating Cocaine-Dependent Individuals - 2</brief_title>
	<detailed_description>Memantine non-competitive NMDA receptor antagonist work decrease normal excitement brain . Dopamine play role reward addictive property cocaine , however , past clinical study successful use dopamine agonist treat cocaine dependent individual . Non-competitive NMDA receptor antagonist show reduce cocaine-induced dopamine release animal model lessen conditioned cocaine cue . This study evaluate memantine treat cocaine dependent individual ability prevent relapse cocaine use . Specifically , aim study determine memantine superior placebo decrease cocaine craving , psychological symptom , functional impairment , discontinuation treatment cocaine abuse . Participants enter 2-week , single-blind , placebo lead-in phase , visit clinic three time week . At study visit , urine sample rating assessment collect . In addition , participant attend weekly therapy session . In order continue trial , participant require attend least four first six study visit therapy session . Eligible participant randomly assign receive either memantine placebo duration 12-week , double-blind phase trial . Study visit continue occur three time week ; participant also receive weekly therapy . Memantine take twice day . Participants complete 12-week trial enter 2-week lead-out phase , taper back placebo single-blind manner . Weekly psychotherapy session continue end Week 14 .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Meets DSMIV criterion current cocaine dependence Use cocaine least four day month prior enrollment episodic cocaine binge least $ 200 worth least twice month ( confirmed urine toxicology test ) Meets DSMIV criterion major depression , bipolar disorder , schizophrenia , psychotic disorder transient psychosis due drug abuse History seizures two year prior enrollment History seizure related current substance abuse ( include cocaine , alcohol , benzodiazepine ) History allergic reaction memantine Chronic organic mental disorder Current significant suicidal risk , history significant suicidal behavior , suicide attempt within year prior enrollment Pregnant breastfeeding Failure use adequate contraception Unstable physical disorder might make participation hazardous , hypertension , acute hepatitis ( individual chronic mildly elevated transaminase level 2 3 time upper normal limit exclude PT/PTT normal ) , renal impairment , diabetes Current coronary vascular disease , suspect abnormal ECG history cardiac symptom Cardiac conduction system disease , indicate QRS duration great 0.11 History failure respond previous trial memantine Currently meet DSMIV criterion substance dependence abuse disorder nicotine marijuana Currently take psychotropic medication , exclude zolpidem trazodone insomnia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cocaine dependence</keyword>
	<keyword>treatment</keyword>
	<keyword>memantine</keyword>
</DOC>